Chronic Lymphocytic Leukemia
An indolent clonal B-cell leukemia characterized by progressive accumulation of mature-appearing but dysfunctional lymphocytes, leading to lymphadenopathy and bone marrow failure.
Emergency Management: Tumor Lysis Syndrome (TLS) can occur during the initiation of Venetoclax, presenting with hyperkalemia, hyperuricemia, hyperphosphatemia, and acute kidney injury. Requires aggressive hydration and allopurinol/rasburicase prophylaxis.
Chronic lymphocytic leukemia (CLL) is a low-grade, indolent clonal lymphoproliferative disorder characterized by the progressive accumulation of functionally incompetent monoclonal B lymphocytes in the blood, bone marrow, lymph nodes, and spleen. It is the most common leukemia in adults in Western countries. The leukemic cells are typically small, mature-appearing lymphocytes expressing CD5, CD19, CD20, and CD23.
Detailed Overview
CLL typically has a highly variable clinical course; some patients remain asymptomatic for decades, while others experience rapid disease progression requiring early intervention. The pathogenesis is driven by continuous B-cell receptor (BCR) signaling and anti-apoptotic mechanisms within the tumor microenvironment, particularly involving BCL-2 overexpression. The disease inevitably progresses to widespread lymphadenopathy, hepatosplenomegaly, and progressive bone marrow failure leading to cytopenias. Transformation to a high-grade lymphoma (Richter's transformation) occurs in 2-10% of cases.
Epidemiology & Demographics
Incidence is 4.6 per 100,000 persons per year in the US. Median age at diagnosis is 70 years. It is twice as common in males as in females (M:F ratio 2:1). Extremely rare in Asian populations. Prevalence is approximately 130,000 cases in the US.
Etiological Mechanism
The exact cause is unknown, but chromosomal aberrations are highly implicated. The most common cytogenetic abnormalities include del(13q) (most common, good prognosis), trisomy 12, del(11q), and del(17p) (TP53 mutation, worst prognosis).
Primary Causes
Genetic predisposition (familial CLL accounts for 5-10% of cases)
Acquired chromosomal deletions and mutations (e.g., del(13q14), TP53, ATM, NOTCH1)
CLL arises from the malignant transformation of mature, antigen-experienced B cells. These leukemic cells exhibit impaired apoptosis due to overexpression of the anti-apoptotic protein BCL-2 and reliance on B-cell receptor (BCR) signaling pathways, including Bruton tyrosine kinase (BTK) and PI3K. The cells accumulate in the G0/G1 phase of the cell cycle and rely heavily on the microenvironment in lymph nodes and bone marrow for survival signals (via CD40/CD40L and chemokines like CXCL12/CXCR4). Over time, the expanding leukemic clone crowds out normal hematopoiesis, leading to anemia and thrombocytopenia, and disrupts immune function, causing hypogammaglobulinemia.
Diagnostic Criteria & Guidelines
Diagnosis requires absolute clonal B-lymphocytosis ≥ 5,000/mcL (5 x 10^9/L) in the peripheral blood, sustained for at least 3 months. Flow cytometry must demonstrate clonality (kappa or lambda light chain restriction) and the characteristic immunophenotype: CD5+, CD19+, CD20+ (dim), CD23+, and surface immunoglobulin dim.
For asymptomatic patients (Rai 0-II), 'watch and wait' is standard. For symptomatic or advanced disease (Rai III-IV, bulky lymphadenopathy, severe B symptoms): Targeted agents are preferred. IGHV unmutated or TP53 mutated (del17p): Acalabrutinib 100 mg PO BID or Zanubrutinib 160 mg PO BID (BTK inhibitors). Alternatively, Venetoclax (BCL-2 inhibitor) starting at 20 mg PO daily with 5-week ramp-up to 400 mg daily, combined with Obinutuzumab (anti-CD20) 1000 mg IV on days 1, 8, 15 of cycle 1 and day 1 of cycles 2-6.
Second-Line & Adjunctive Therapy
If progressing on BTK inhibitor: Venetoclax-based regimen. If progressing on Venetoclax: Covalent BTK inhibitor or non-covalent BTK inhibitor (Pirtobrutinib 200 mg PO daily). CAR T-cell therapy (e.g., Lisocabtagene maraleucel) in clinical trials for relapsed/refractory cases.
Surgical & Procedural Management
Splenectomy may be indicated for massive symptomatic splenomegaly refractory to medical therapy or severe refractory autoimmune hemolytic anemia/ITP.
Patient Counseling & Advice
CLL is generally not curable but is highly treatable. Explain the rationale behind 'watch and wait' for early-stage disease to prevent anxiety, emphasizing that early treatment does not improve overall survival but introduces toxicity. Review signs of disease progression (B symptoms, rapidly enlarging nodes).
Follow-Up & Monitoring Schedule
Asymptomatic patients: CBC with differential and clinical examination every 3-6 months. Symptomatic/Treated: Regular CBC, CMP, and specific monitoring for drug toxicities (e.g., bleeding risk and atrial fibrillation with ibrutinib; tumor lysis syndrome risk during venetoclax ramp-up).
Preventive Strategies
No known preventive measures. Avoidance of live vaccines is critical to prevent vaccine-strain infections.
Highly variable. Patients with isolated del(13q) and mutated IGHV have median survival >10-15 years, often normal life expectancy. Patients with del(17p) or TP53 mutation historically had survival <3-5 years, but targeted therapies have significantly improved outcomes.